Introduction {#s1}
============

Multiple sclerosis (MS) is an inflammatory disease of the central nervous system characterised by demyelination and axonal loss.[@pone.0010142-Noseworthy1] Studies conducted in mono- and dizygotic twin pairs and siblings have shown that genetics plays a role in MS susceptibility.[@pone.0010142-Willer1] Linkage was effective in identifying the locus exerting the single strongest genetic effect in MS, namely, the human leukocyte antigen (HLA) class II region.[@pone.0010142-Ebers1] The risk associated with this region has since been shown to be determined by epistatic interactions between different HLA alleles,[@pone.0010142-Lincoln1] and is thought to be responsible for approximately 50% of the genetic risk of MS.[@pone.0010142-Peltonen1] Beyond this powerful determinant of MS genetic susceptibility, research has taken considerably longer to bear useful fruit. Finally, after the genotyping of hundreds of thousands of single nucleotide polymorphisms (SNPs) in many thousands of MS patients and controls, we are beginning to establish a network of loci outside of the HLA region involved in determining MS susceptibility.[@pone.0010142-Burton1], [@pone.0010142-Hafler1], [@pone.0010142-IMSGC1], [@pone.0010142-Ban1], [@pone.0010142-DeJager1], [@pone.0010142-DeJager2], [@pone.0010142-Hafler2], [@pone.0010142-Baranzini1], [@pone.0010142-Rubio1], [@pone.0010142-ANZgene1], [@pone.0010142-Kallio1], [@pone.0010142-Jakkula1] It is worth considering that even the most strongly associated of these with MS is still a significantly weaker determinant of MS susceptibility than HLA alleles. For some of these loci, functional studies have been undertaken.[@pone.0010142-DeJager2], [@pone.0010142-Gregory1], [@pone.0010142-Maier1] However, such studies are rarely carried out in an unbiased manner since these generally correlate genetic variations with the expression of a candidate gene. A recent study of mRNA levels in MS patients and healthy controls showed a great multitude of differentially expressed genes however it is uncertain to what extent this reflects the aetiology of disease as opposed to the disease process or adaptive biological pathways.[@pone.0010142-Gandhi1]

A recent investigation has performed whole genome expression analysis in lymphoblastoid cell lines (LCLs) from healthy volunteers who were also genotyped for a large number of SNPs.[@pone.0010142-Dixon1] We used the data from this study to examine the effects of current susceptibility loci in MS on gene expression.

Methods {#s2}
=======

Gene expression analysis {#s2a}
------------------------

This was carried out as described in Dixon *et al.* [@pone.0010142-Dixon1] Briefly, peripheral lymphocytes were transformed using Epstein-Barr virus before being cultured, pelleted and frozen for storage. cDNA templates were created using the One-Cycle cDNA Synthesis Kit (Affymetrix). *In vitro* transcription of cDNA was performed using the IVT Labeling Kit (Affymetrix) and, after hybridisation on U133 Plus 2.0 GeneChips (Affymetrix), this was scanned using a high-resolution scanner (Affymetrix). Whole-genome genotyping was carried out according to manufacturers\' instructions using the Sentrix Human-1 Genotyping BeadChip and the HumanHap300 Genotyping BeadChip. The analysis of expression was carried out on the publically available database of mRNA by SNP Browser 1.0 as described.[@pone.0010142-Dixon1]

mRNA by SNP analysis {#s2b}
--------------------

We investigated the mRNAs significantly altered in expression by the SNPs reported in the literature to be at or close to genome-wide significance.[@pone.0010142-Burton1], [@pone.0010142-Hafler1], [@pone.0010142-IMSGC1], [@pone.0010142-Ban1], [@pone.0010142-DeJager1], [@pone.0010142-DeJager2], [@pone.0010142-Hafler2], [@pone.0010142-Baranzini1], [@pone.0010142-Rubio1], [@pone.0010142-ANZgene1], [@pone.0010142-Kallio1], [@pone.0010142-Jakkula1] If the susceptibility SNP was not available on the database, we used the SNP with the strongest linkage disequilibrium (LD) with the susceptibility SNP as provided by SNP Browser 1.0 based on r^2^. For SNPs where no proxy was provided, we investigated all genotyped SNPs within 500 kb for LD with r^2^≥0.4 for a suitable proxy SNP. We also assessed the degree of LD with potentially interesting SNPs within 500 kb of the original susceptibility SNP. Finally we assessed the SNPs associated with expression of putative candidate genes to ensure that we did not miss any important associations with expression.

Results {#s3}
=======

SNP selection {#s3a}
-------------

We chose to look at a set of 38 SNPs which were the top loci to reach genome-wide significance selected from currently reported genome wide association studies (GWAS) of which 14 had been independently replicated in 2 studies. 17 of these were not present in the genome-wide association mRNA expression library and so when possible proxy SNPs in strong-to-moderate LD were used instead. The SNPs and proxy SNPs used are detailed in [**Table 1**](#pone-0010142-t001){ref-type="table"}.
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###### SNPs and proxy SNPs analysed.

![](pone.0010142.t001){#pone-0010142-t001-1}

  SNP           putative gene association       proxy SNP         r^2^
  ------------ --------------------------- -------------------- ---------
  rs1054283                IL7                                  
  rs10876994      METTL1, CYP27B1, CDK4         rs10083154       0.70067
  rs1132200              TMEM39A                                
  rs11554159              IFI30                  rs874628         0.949
  rs11808092            EVI5-RPL5                               
  rs11865121             CLEC16A                rs2041670           1
  rs12122721             KIF21B                                 
  rs12368653      METTL1, CYP27B1, CDK4                         
  rs12708716             CLEC16A                 rs725613           1
  rs12722489              IL2RA                 rs12722561       0.9349
  rs1335532               CD58                  rs6677309           1
  rs1569723               CD40                                  
  rs17445836              IRF8                                  
  rs17824933               CD6                  rs2237997        0.43718
  rs1800693             TNFRSF1A                                
  rs2051322               CD226                                 
  rs2104286               IL2RA                 rs12722561        0.548
  rs2300747               CD58                  rs6677309           1
  rs2523393            HLA class I              rs2394160        0.96552
  rs2587156                IL7                                  
  rs3129860           HLA class II              rs9271366        0.95557
  rs3129934      C6orf10, BTNL2, NOTCH4         rs9267992        0.95604
  rs3135388           HLA class II              rs9271366        0.95699
  rs34536443              TYK2              No proxy available  
  rs4149584             TNFRSF1A            No proxy available  
  rs441349                SOCS1                 rs1646042           1
  rs6074022               CD40                                  
  rs6131010               CD40                  rs6074022        0.70337
  rs6604026             EVI5-RPL5                               
  rs6860438                C7                                   
  rs6897932               IL7R                                  
  rs703842        METTL1, CYP27B1, CDK4                         
  rs7404554              CLEC16A                                
  rs744166                STAT3                                 
  rs763361                CD226                                 
  rs8118449               TYK2              No proxy available  
  rs9271366           HLA class II                              
  rs9523762               GPC5                                  

mRNA expression {#s3b}
---------------

13 of the MS susceptibility SNPs or proxy SNPs were associated with changes in mRNA expression (**[Table S1](#pone.0010142.s001){ref-type="supplementary-material"}**). Two SNPs in strong LD with multiple MS-associated SNPs in the HLA region were related to expression of various HLA alleles, including *HLA-DQA1*, *HLA-DQA2*, *HLA-DQB1*, *HLA-DRB1*, *HLA-DRB4* and *HLA-DRB5*. One SNP in the HLA class I region was associated with altered expression of *ZFP57*. Both SNPs in CD58 were associated with expression of *CD58*. A SNP in the IL7 region was associated with expression of mRNA encoding *IL7* and *FAM164A*. Three SNPs in the region of METTL1-CYP27B1-CDK4 altered the expression of several genes: *FAM119B*, *TSFM* and *KUB3*. The common gene of altered expression for all three SNPs was *TSFM*.

Overlap with previous mRNA expression studies {#s3c}
---------------------------------------------

We used the supplemental data supplied by Gandhi and colleagues to examine cross-over between the results obtained in that study and the genes we identified as being altered in expression by susceptibility SNPs.[@pone.0010142-Gandhi1] Only three genes were in common between the two sets: *HLA-DQB1*, *HLA-DRB1* and *STAT3*. *HLA-DRB1* was upregulated in MS, relapsing-remitting MS (RRMS) and secondary progressive MS compared with healthy controls. *HLA-DQB1* expression was reduced in MS and RRMS compared with healthy controls. *STAT3* was reduced in primary progressive MS compared with healthy controls.

Discussion {#s4}
==========

Our findings show that some, but by no means all, susceptibility SNPs in MS are associated with changes in gene expression. Some of these (*CD58*, had already been noted by previous investigators.[@pone.0010142-DeJager2] We were unable to find supporting evidence in this dataset for the previously reported allelic effect of the susceptibility SNP in *IL7R* on expression of the gene.[@pone.0010142-Gregory1] Similarly, SNPs in the *IL2RA* gene did not correlate with expression of *IL2RA* mRNA, despite previously finding altered levels of this in MS patients relative to controls.[@pone.0010142-Maier1]

We also found several novel effects of susceptibility SNPs. Two SNPs in tight LD with susceptibility SNPs in the *HLA* region correlated with expression of several *HLA* class II mRNAs. However, measuring gene expression in the HLA is a complex task. There is haplotype specificity for some genes (*HLA-DRB4* and *HLA-DRB5*) and thus we are not sure whether differential expression of HLA genes measured by microarray reflects different probe affinity for different HLA class II alleles and thus further work is needed to fully understand this association. Our identification that a SNP in the *HLA* class I region was associated with altered expression of *ZFP57* is an interesting observation as this gene has been linked with DNA methylation changes across the genome resulting in transient neonatal diabetes.[@pone.0010142-Mackay1] There is some epidemiological evidence that MS may be partly determined by epigenetic alterations and this would be an ideal candidate functionally linking MS to the epigenome.[@pone.0010142-Handel1] A SNP in *IL7* recently confirmed as associated with MS was shown to correlate with the expression of several genes: *IL7* and *FAM164A*. Naturally the most compelling candidate of these is *IL7* due to its probable role in autoimmunity. However, the advantage of an unbiased screen is that it raises the possibility of candidate genes that would otherwise not be considered. This is especially so since the SNP is far more strongly associated with *FAM164A* expression than with *IL7*. *FAM164A* is a hypothetical protein encoded in the reverse direction to *IL7* and its functional importance is largely unknown.[@pone.0010142-Kono1] The susceptibility region on chromosome 12 was previously linked with the expression of *FAM119B*.[@pone.0010142-Gandhi1] We feel that the relationship of all three major susceptibility SNPs with the expression of *TSFM* suggests this as a strong candidate. This is a plausible candidate in terms of function too as it is involved in the translation of mitochondrial proteins, providing a potential link with other susceptibility genes linked to mitochondrial function, such as *KIF21B*.[@pone.0010142-IMSGC1], [@pone.0010142-Smeitink1] Further functional work will be needed to better assess these candidates.

The limited cross-over between known and suspected susceptibility genes in the whole genome expression analysis of Gandhi and colleagues is likely due to a number of differences including the use of whole blood mRNA and individuals with established disease in the Gandhi study.[@pone.0010142-Gandhi1] It is possible that future whole genome analyses of expression conducted using RNA-seq in cell-sorted samples of patients with very early disease may reveal alterations in the level of susceptibility gene mRNA.

The advantage of an unbiased approach to linking the expression of genes with genetic variation associated with disease susceptibility is that there is no *a priori* hypothesis to blind investigators to the presence of other genes. There are several limitations to the approach we used. The mRNA screen was conducted in transformed LCLs and so it would not be informative about tissue-specific gene expression.[@pone.0010142-Dixon1] Also, SNP coverage across the genome was not complete and so the functional effects of some SNPs for which no proxy was available will be concealed. Furthermore, despite using expression data from 400 LCLs, we may have been underpowered to detect relevant effects. However, our finding of several novel associations between MS SNPs and gene expression is worthy of further investigation and also raises the hypothesis that some disease associated SNPs may not exert their effects on MS susceptibility through simple effects on gene expression.

Supporting Information {#s5}
======================
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Changes in mRNA expression associated with susceptibility SNPs.
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Click here for additional data file.
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